New share issue provides Bluefish with approximately SEK 41 million

The pharmaceutical company Bluefish has completed three directed new share issues, which in total provides the company with approximately SEK 41 million. In addition, the convertible debenture serie 2011/14 has been reduced from SEK 60 million to SEK 32 million, partly through conversion to shares equivalent to an amount of SEK 20 million, partly through redemption and re-subscription in the convertible debenture serie 2013/17 with maturity date 30 June 2017 equivalent to an amount of SEK 8 million.

Through the new share issues and partial conversion of the convertible debenture serie 2011/14, the total number of shares in Bluefish has increased by 12 139 309. The subscription price was SEK 5 for each new share. Following these transactions, the total number of shares in Bluefish amounts to 70 942 496 and the share capital amounts to SEK 14 188 499.

The new share issues, together with the conversion and extension of the convertible debenture, secure the company’s liquidity and strengthen the capital structure.

For more information, contact

Karl Karlsson, President & CEO Bluefish Pharmaceuticals
Tel. 46 8 519 116 00
Email: karl.karlsson@bluefishpharma.com

Susanna Urdmark, CFO Bluefish Pharmaceuticals
Tel. 46 8 519 116 00
Email: susanna.urdmark@bluefishpharma.com

About Bluefish Pharmaceuticals
Bluefish has undergone significant international expansion since the company was founded in 2005. Bluefish focuses on the development, manufacture and sale of generic pharmaceuticals. The company conducts marketing operations in a large number of European markets and has a technology center in Bangalore, India. The product portfolio consists of a total of 80 products and is growing.

www.bluefishpharma.com